Edgewise Therapeutics Inc [EWTX] stock is trading at $15.44, down -4.81%. An important factor to consider is whether the stock is rising or falling in short-term value. The EWTX shares have lost -6.93% over the last week, with a monthly amount glided 3.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Edgewise Therapeutics Inc [NASDAQ: EWTX] stock has seen the most recent analyst activity on September 25, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $20. Previously, Raymond James started tracking the stock with Strong Buy rating on July 30, 2025, and set its price target to $46. On June 30, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $42 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $41 on April 30, 2025. Scotiabank downgraded its rating to a Sector Perform but $14 remained the price target by the analyst firm on April 02, 2025. Scotiabank started tracking with a Sector Outperform rating for this stock on March 07, 2025, and assigned it a price target of $50. In a note dated January 22, 2025, Stifel initiated an Hold rating and provided a target price of $30 on this stock.
Edgewise Therapeutics Inc [EWTX] stock has fluctuated between $10.60 and $38.12 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Edgewise Therapeutics Inc [NASDAQ: EWTX] shares were valued at $15.44 at the most recent close of the market. An investor can expect a potential return of 29.53% based on the average EWTX price forecast.
Analyzing the EWTX fundamentals
Gross Profit Margin for this corporation currently stands at -1.11% with Operating Profit Margin at -82.41%, Pretax Profit Margin comes in at -71.15%, and Net Profit Margin reading is -71.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.31 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.08 points at the first support level, and at 14.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.12, and for the 2nd resistance point, it is at 16.79.
Ratios To Look Out For
For context, Edgewise Therapeutics Inc’s Current Ratio is 28.87. On the other hand, the Quick Ratio is 28.87, and the Cash Ratio is 2.08.
Transactions by insiders
Recent insider trading involved Russell Alan J, Chief Scientific Officer, that happened on Aug 26 ’25 when 100000.0 shares were sold. Officer, ALAN J RUSSELL completed a deal on Aug 26 ’25 to buy 100000.0 shares. Meanwhile, General Counsel MOORE JOHN R sold 2098.0 shares on Aug 12 ’25.
